BIO-TECHNE Corp (TECH) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.56M; Additional Paid in Capital, Common StockUSD $1.03B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-70.58M; Retained Earnings (Accumulated Deficit)USD $1.14B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.56M; Additional Paid in Capital, Common StockUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-66.86M; Retained Earnings (Accumulated Deficit)USD $1.15B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.56M; Additional Paid in Capital, Common StockUSD $964.96M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-62.34M; Retained Earnings (Accumulated Deficit)USD $1.11B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.56M; Additional Paid in Capital, Common StockUSD $946.12M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-64.39M; Retained Earnings (Accumulated Deficit)USD $1.08B.
BIO-TECHNE Corp Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Noncontrolling Interest, Increase from Sale of Parent Equity Interest USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Noncontrolling Interest, Increase from Business Combination USD | Noncontrolling Interest, Decrease from Deconsolidation USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.56M | $1.03B | $-70.58M | $1.14B | $2.11B | (m) | 12 month · $858.00K | 12 month · $40.51M | (m) | 12 month · 45.82 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.56M | $1.01B | $-66.86M | $1.15B | $2.09B | $2.09B | 3 month · $190.00K | 3 month · $10.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.56M | $964.96M | $-62.34M | $1.11B | $2.01B | $2.01B | 3 month · $373.00K | 3 month · $13.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.56M | $946.12M | $-64.39M | $1.08B | (m) | $1.97B | 3 month · $-2.00K | 3 month · $11.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.55M | $911.09M | $-59.88M | $1.07B | $1.92B | $1.92B | 12 month · $825.00K | 12 month · $40.01M | (m) | 12 month · 60.60 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.57M | $902.12M | $-82.05M | $1.20B | $2.02B | $2.02B | 3 month · $35.00K | 3 month · $11.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.58M | $875.86M | $-85.65M | $1.29B | $2.08B | $2.08B | 3 month · $373.00K | 3 month · $14.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.59M | $855.97M | $-60.09M | $1.34B | $2.14B | $2.14B | 3 month · $38.00K | 3 month · $10.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.58M | $820.34M | $-78.32M | $1.33B | $2.07B | $2.07B | 12 month · $906.00K | 12 month · $37.14M | (m) | 12 month · 57.28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.58M | $790.42M | $-75.31M | $1.30B | $2.01B | $2.01B | 3 month · $80.00K | 3 month · $8.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.57M | $764.27M | $-63.66M | $1.26B | $1.96B | $1.96B | 3 month · $340.00K | 3 month · $12.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.58M | $746.61M | $-78.02M | $1.33B | $2.00B | $2.00B | 3 month · $112.00K | 3 month · $9.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.58M | $721.54M | $-66.06M | $1.31B | $1.97B | $1.97B | 12 month · $915.00K | 12 month · $38.31M | 12 month · $613.00K | 12 month · 88.12 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.57M | $715.05M | $-73.55M | $1.25B | $1.89B | $1.89B | 3 month · $113.00K | 3 month · $9.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.57M | $700.68M | $-75.12M | $1.20B | $1.83B | $1.83B | 3 month · $333.00K | 3 month · $16.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $392.00K | $680.06M | $-91.81M | $1.16B | $1.75B | $1.75B | 3 month · $97.00K | 3 month · $14.36M | (m) | (m) | (m) | (m) | (m) | 3 month · $613.00K | (m) | (m) |
| 2022-06-30 | $1.57M | $652.47M | $-75.20M | $1.12B | $1.70B | $1.70B | 12 month · $973.00K | 12 month · $41.21M | (m) | 12 month · 102.06 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $393.00K | $636.32M | $-55.15M | $1.13B | $1.71B | $1.71B | 3 month · $25.00K | 3 month · $8.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $393.00K | $616.43M | $-59.47M | $1.15B | $1.70B | $1.70B | 3 month · $267.00K | 3 month · $13.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $393.00K | $583.85M | $-64.22M | $1.12B | $1.64B | $1.65B | 3 month · $341.00K | 3 month · $11.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $390.00K | $534.41M | $-57.29M | $1.09B | $1.56B | $1.57B | 12 month · $917.00K | 12 month · $48.06M | (m) | 12 month · 89.95 | (m) | (m) | 12 month · $8.98M | (m) | (m) | (m) |
| 2021-03-31 | $389.00K | $514.30M | $-64.02M | $1.09B | $1.54B | $1.55B | 3 month · $411.00K | 3 month · $10.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $388.00K | $481.00M | $-64.24M | $1.10B | $1.52B | $1.53B | 3 month · $106.00K | 3 month · $15.47M | (m) | (m) | (m) | (m) | 3 month · $8.98M | (m) | (m) | (m) |
| 2020-09-30 | $386.00K | $448.68M | $-83.14M | $1.07B | $1.44B | $1.44B | 3 month · $286.00K | 3 month · $12.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $385.00K | $420.54M | $-97.20M | $1.06B | $1.38B | $1.38B | 12 month · $435.00K | 12 month · $31.93M | (m) | 12 month · 179.37 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $381.00K | $381.63M | $-103.46M | $1.01B | $1.29B | $1.29B | 3 month · $110.00K | 3 month · $7.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $383.00K | $362.53M | $-78.35M | $1.04B | $1.32B | $1.32B | 3 month · $112.00K | 3 month · $10.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $381.00K | $334.11M | $-91.63M | $931.36M | $1.17B | $1.17B | 3 month · $99.00K | 3 month · $8.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $379.00K | $316.80M | $-83.52M | $931.93M | $1.17B | $1.17B | 12 month · $505.00K | 12 month · $31.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $378.00K | $297.75M | $-79.63M | $927.77M | $1.15B | (m) | 3 month · $84.00K | 3 month · $5.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $377.00K | $283.85M | $-83.01M | $895.21M | $1.10B | (m) | 3 month · $77.00K | 3 month · $6.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $378.00K | $274.58M | $-70.63M | $905.14M | $1.11B | (m) | 3 month · $238.00K | 3 month · $11.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $376.00K | $246.57M | $-44.81M | $876.93M | $1.08B | $1.08B | 12 month · $281.00K | 12 month · $27.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $375.00K | $226.47M | $-15.86M | $847.31M | $1.06B | (m) | 3 month · $78.00K | 3 month · $4.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $375.00K | $214.70M | $-56.82M | $839.56M | $997.82M | (m) | 3 month · $59.00K | 3 month · $4.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $374.00K | $206.76M | $-49.76M | $802.43M | $960.08M | (m) | 3 month · $77.00K | 3 month · $3.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $374.00K | $199.16M | $-48.94M | $799.03M | $949.63M | (m) | 12 month · $213.00K | 12 month · $14.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $514.00K |
| 2017-03-31 | $373.00K | $194.01M | $-65.29M | $778.84M | $907.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $373.00K | $188.41M | $-67.22M | $769.00M | $890.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $373.00K | $184.21M | $-63.92M | $774.73M | $895.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $372.00K | $178.76M | $-70.41M | $770.55M | $879.28M | (m) | 12 month · $144.00K | 12 month · $9.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $566.00K |
| 2016-03-31 | $372.00K | $172.14M | $-76.48M | $756.93M | $852.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $372.00K | $168.96M | $-51.53M | $738.54M | $856.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $372.00K | $166.60M | $-53.62M | $724.59M | $837.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $371.00K | $163.31M | $-30.59M | $713.85M | $846.93M | (m) | 12 month · $39.00K | 12 month · $5.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $615.00K |
| 2015-03-31 | $372.00K | $161.85M | $-41.62M | $699.47M | $820.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $0.00 | (m) |
| 2014-12-31 | $371.00K | $157.73M | $-24.48M | $687.06M | $820.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $0.00 | (m) |
| 2014-09-30 | $370.00K | $150.31M | $-22.98M | $665.71M | $793.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $0.00 | (m) |
| 2014-06-30 | $370.00K | $147.00M | $-5.39M | $653.28M | $795.26M | (m) | (m) | 12 month · $3.52M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $618.00K | 12 month · $262.00K |
| 2014-03-31 | $369.00K | $142.66M | $-3.91M | $637.92M | $777.04M | (m) | (m) | (m) | (m) | (m) | $-12.30M | $8.39M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $369.00K | $140.39M | $-9.95M | $617.72M | $748.53M | (m) | (m) | (m) | (m) | (m) | $-13.04M | $3.08M | (m) | (m) | (m) | (m) |
| 2013-09-30 | $369.00K | $136.61M | $-14.32M | $604.10M | $726.76M | (m) | (m) | (m) | (m) | (m) | $-16.38M | $2.06M | (m) | (m) | (m) | (m) |
| 2013-06-30 | $368.00K | $134.90M | $14.55M | $587.73M | $737.54M | (m) | (m) | 12 month · $1.86M | (m) | (m) | $-24.28M | $38.83M | (m) | (m) | (m) | 12 month · $75.00K |
| 2013-03-31 | $368.00K | $134.12M | $12.84M | $572.19M | $719.51M | (m) | (m) | (m) | (m) | (m) | $-24.98M | $37.81M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $368.00K | $133.83M | $10.25M | $550.12M | $694.57M | (m) | (m) | (m) | (m) | (m) | $-15.71M | $25.96M | (m) | (m) | (m) | (m) |
| 2012-09-30 | $368.00K | $132.29M | $12.14M | $535.80M | $680.61M | (m) | (m) | (m) | (m) | (m) | $-16.82M | $28.96M | (m) | (m) | (m) | (m) |
| 2012-06-30 | $368.00K | $131.85M | $21.77M | $520.45M | $674.44M | (m) | (m) | 12 month · $1.64M | (m) | (m) | $-20.74M | $42.52M | (m) | (m) | (m) | 12 month · $51.00K |
| 2012-03-31 | $369.00K | $131.42M | $6.88M | $505.83M | $644.50M | (m) | (m) | (m) | (m) | (m) | $-17.65M | $24.53M | (m) | (m) | (m) | (m) |
| 2011-12-31 | $369.00K | $130.52M | $-20.90M | $487.52M | $597.51M | (m) | (m) | (m) | (m) | (m) | $-21.55M | $641.00K | (m) | (m) | (m) | (m) |
| 2011-09-30 | $370.00K | $129.65M | $-20.22M | $479.55M | $589.35M | (m) | (m) | (m) | (m) | (m) | $-20.84M | $620.00K | (m) | (m) | (m) | (m) |
| 2011-06-30 | $371.00K | $129.31M | $-16.29M | $472.73M | $586.12M | (m) | (m) | 12 month · $1.14M | (m) | (m) | $-16.94M | $648.00K | (m) | (m) | (m) | 12 month · $847.00K |
| 2011-03-31 | $371.00K | $127.32M | $-15.84M | $454.43M | $566.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $371.00K | $127.23M | $-19.05M | $433.39M | $541.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $371.00K | $123.62M | $-17.29M | $416.86M | $523.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $370.00K | $122.54M | $-21.23M | $400.12M | $501.79M | (m) | (m) | 12 month · $1.14M | (m) | (m) | $-21.97M | $733.00K | (m) | (m) | (m) | 12 month · $196.00K |
| 2009-06-30 | (m) | (m) | $-7.48M | (m) | $456.48M | (m) | (m) | 12 month · $1.48M | (m) | (m) | $-8.04M | $558.00K | (m) | (m) | (m) | 12 month · $107.00K |
| 2008-06-30 | (m) | (m) | (m) | (m) | $487.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |